Jazz Pharmaceuticals (JAZZ) Stock Price
$97.78 0%
to add to portfolio
AI Score
-
Alternative
3 -
Fundamental
5 -
Technical
4
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Jazz Pharmaceuticals, AI stock picks, stock alerts and much more.
JAZZ AI Stock Analysis
AI stock analysis for JAZZ is missing at the moment.
Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Jazz Pharmaceuticals (JAZZ) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.
Sign up and become a member to get access to AI stock analysis.
Sign up
Jazz Pharmaceuticals (JAZZ) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Jazz Pharmaceuticals (JAZZ), currently trading at $97.78, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About JAZZ
-
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally.
-
Symbol
JAZZ
-
Market
NASDAQ
-
Industry
Biotechnology
-
Market Cap
6B
Similar Stocks
 |
Catalyst Pharmaceuticals CPRX |
$23.37 2.7% |
6 |
 |
Inovio Pharmaceuticals INO |
$1.8 1.1% |
1 |
 |
Moderna MRNA |
$24.25 0.5% |
3 |
 |
Anavex Life Sciences AVXL |
$8.25 3.6% |
5 |
 |
BridgeBio Pharma BBIO |
$34.17 2% |
6 |
News
JAZZ Alternative Data
Web Traffic
Jazz Pharmaceuticals receives an estimated 66219 monthly visitors to jazzpharma.com, which is down by -16.1% over the last month.
-
Web Traffic
66219
-
Change from Previous Month
16.1%
-
3 Month Change
28%
-
YoY Change
28%
Reddit Mentions
Jazz Pharmaceuticals has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
100%
Twitter Followers
Jazz Pharmaceuticals has 3,557 Twitter Followers on its main Twitter (also known as X) account.
-
Twitter Followers
3557
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0.5%
-
YoY Change
0.5%
Job Postings
Jazz Pharmaceuticals currenly has an estimated 64 open job postings, up by 28% over the last month.
-
Job Postings
64
-
Daily Change
0%
-
1 Month Change
28%
-
3 Month Change
20.8%
-
YoY Change
20.8%
LinkedIn Employees
According to LinkedIn, Jazz Pharmaceuticals has 3,411 employees, down by -0.4% over the last month.
-
LinkedIn Employees
3411
-
Daily Change
0.1%
-
1 Month Change
0.4%
-
3 Month Change
0.6%
-
YoY Change
0.6%
LinkedIn Followers
188,155 are following Jazz Pharmaceuticals on LinkedIn.
-
LinkedIn Followers
188155
News Mentions
Jazz Pharmaceuticals was mentioned 0 times in the news yesterday.
-
News Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
100%
Business Outlook
According to employee reviews, the business outlook among employees at Jazz Pharmaceuticals is 37 out of 100 (bearish).
-
Business Outlook
37
-
Change from Previous Month
0%
-
3 Month Change
0%
-
YoY Change
0%
JAZZ Financials
JAZZ Key Metrics
-
Total Revenue
$1.1B
-
Net Income
$191.1M
-
Earnings per Share
$3.16
-
Free cash flow
$385.3M
-
EBITDA
$190.8M
-
EBITDA Ratio
0.175312
-
Total Assets
$12B
JAZZ 2-year Revenue & Income
JAZZ 2-year Free Cash Flow
JAZZ Technicals
JAZZ SMA
JAZZ RSI
FAQ
What's the current price of Jazz Pharmaceuticals (JAZZ) Stock?
The price of an Jazz Pharmaceuticals (JAZZ) share is $97.78.
What's the market cap of Jazz Pharmaceuticals?
The current market cap of Jazz Pharmaceuticals is 6B.
Should I buy or sell JAZZ?
Jazz Pharmaceuticals shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, Jazz Pharmaceuticals is better viewed as a hold or accumulate position while waiting for further developments.
Is Jazz Pharmaceuticals a good investment?
The current analysis of Jazz Pharmaceuticals' fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in Jazz Pharmaceuticals' portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.
Is now a good time to buy Jazz Pharmaceuticals (JAZZ) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for Jazz Pharmaceuticals stock is currently neutral, suggesting a cautious approach might be wise.
What are some stocks similar to Jazz Pharmaceuticals (JAZZ) that investors often compare it to?
Jazz Pharmaceuticals (JAZZ) is often compared to similar stocks such as Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Moderna, Anavex Life Sciences and BridgeBio Pharma.
What is the forecast for Jazz Pharmaceuticals' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Jazz Pharmaceuticals' stock price to be around $93.9 in 2026. Starting from the current price of $97.78, this represents a 4% change in price, indicating a neutral outlook for the stock.
How to buy Jazz Pharmaceuticals (JAZZ) Stock?
Jazz Pharmaceuticals stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Jazz Pharmaceuticals shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.